SOURCE: Trimedyne, Inc.

February 21, 2007 09:30 ET

Trimedyne Featured on MacReport.Net

LAKE FOREST, CA -- (MARKET WIRE) -- February 21, 2007 --Trimedyne, Inc. (OTCBB: TMED) today announced its chairman, Dr. Marvin P. Loeb, was interviewed by MacReport.Net. The audio interview will be available for two months at no charge by visiting and entering "TMED" in the "Stock Symbol" section.

Dr. Loeb discussed the Company's recently announced worldwide marketing alliance with Boston Scientific and Lumenis, Ltd., who will distribute Trimedyne's new Side Firing Laser Fiber as an accessory to Lumenis' Holmium Lasers for the treatment of enlarged prostates in men. About 50% of men over age 55 suffer from an enlarged prostate, an estimated $700 million annual market. Dr. Loeb also described the $600 million potential market for the Company's outpatient laser procedures to treat herniated or ruptured discs in the spine, the Company's 6th consecutive quarterly profit and the Company's financial condition.

Commenting on the interview, Dr. Loeb said, "We are pleased that MacReport chose to interview us, and we are gratified by the attention being paid to Trimedyne's continued profitability and the potential for growth due to its new, worldwide marketing alliance with Boston Scientific and Lumenis."

About MacReport.Net

MacReport.Net is an information and media company that provides a Web-based forum for public and private issuers to bring news content to the attention of the business, financial and investing community through its Web site,

About Trimedyne, Inc.

Trimedyne is a leading manufacturer of proprietary medical lasers and patented fiber optic devices for performing a variety of minimally invasive procedures as a less traumatic, lower cost alternative to surgery. For additional information, visit Trimedyne's website at

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

Statements in this news release and the above mentioned interview may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-K-SB and subsequently filed SEC reports. There is no assurance such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements.

Contact Information